Last reviewed · How we verify
RT+CETUXIMAB
RT+CETUXIMAB combines radiation therapy with cetuximab, an EGFR-blocking monoclonal antibody, to inhibit tumor cell growth and enhance radiosensitivity.
RT+CETUXIMAB combines radiation therapy with cetuximab, an EGFR-blocking monoclonal antibody, to inhibit tumor cell growth and enhance radiosensitivity. Used for Head and neck cancer (squamous cell carcinoma), Locally advanced cancers amenable to radiotherapy.
At a glance
| Generic name | RT+CETUXIMAB |
|---|---|
| Also known as | Radiotherapy, Cetuximab |
| Sponsor | Associazione Volontari Pazienti Oncologici |
| Drug class | EGFR inhibitor (monoclonal antibody) + radiation therapy combination |
| Target | EGFR (epidermal growth factor receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cetuximab binds to the epidermal growth factor receptor (EGFR) on cancer cells, blocking ligand-induced activation and downstream proliferation signaling. When combined with radiation therapy, EGFR inhibition enhances tumor cell radiosensitivity and reduces DNA repair capacity, leading to improved local control and cell death.
Approved indications
- Head and neck cancer (squamous cell carcinoma)
- Locally advanced cancers amenable to radiotherapy
Common side effects
- Acneiform rash
- Radiation dermatitis
- Mucositis
- Dysphagia
- Infusion reactions
- Hypomagnesemia
Key clinical trials
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (PHASE2, PHASE3)
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (PHASE3)
- A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
- Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin (PHASE3)
- Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin (PHASE2, PHASE3)
- Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors (PHASE2)
- RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer (PHASE3)
- Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RT+CETUXIMAB CI brief — competitive landscape report
- RT+CETUXIMAB updates RSS · CI watch RSS
- Associazione Volontari Pazienti Oncologici portfolio CI